Benzinga
26 Feb 2026, 19:19 UTC · 36w ago
COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb
Impact · against what's priced in
Novavax faces a significant valuation headwind due to 2026 revenue guidance ($230M–$270M) coming in well below the analyst consensus of $381.22M. While the shift to profitability and aggressive cost-cutting targets are positive fundamental developments, they are likely secondary to the substantial top-line miss.
- NVAX−0.20
No priced-in read yet
- In context
The company's return to profitability and improved cost management are offset by 2026 revenue guidance that is roughly 30% lower than market expectations of $381.22 million.
Read from the article alone
